Recapping: The Future For Biosimilars (an Atlantic policy briefing)

Tuesday March 28, 2017

On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by The Biosimilars Council, more than 100 influencers from across the country braved a late blast of winter weather to discuss the potential impact on the biosimilars industry of the new administration, changing regulations and recent FDA guidelines on interchangeability and naming.

Comments and discussion among the speakers and panelists confirmed that access to affordable healthcare is very much on the minds of American people as well being a top priority for policymakers on Capitol Hill. Presently, the FDA is working to create biosimilar policies and regulation that provide both patients and physicians with clarity and confidence around biosimilar usage.

While the U.S. has taken a more conservative stance on biosimilars than the European Union, biosimilars have the potential to be an “explosive” part of the U.S. drug market in the next 5-10 years, said Dr. Len Lichtenfeld, Deputy Chief Medical Officer of the American Cancer Society. With the worldwide market for biosimilars estimated to reach $25-$30 billion dollars over the next four years, the possibilities for development and increased patient access to these vital treatments are highly promising.

Our special thanks to all who participated, especially:

  • Representative Michael C. Burgess, M.D. (R-TX), Chairman of the House Energy and Commerce Subcommittee on Health
  • Jim Van Lieshout, Vice President, Market Access and Pharmacy Strategy, Apobiologix
  • Len Lichtenfeld M.D., Deputy Chief Medical Officer, American Cancer Society
  • David Fox, Partner, Hogan Lovells
  • Joie Chen, Journalist and Contributor, AtlanticLIVE


If you were unable to join the live event, full video is available here; review Tweets from participants at


The Biosimilars Council is now on Twitter, Facebook, and LinkedIn, follow us for the latest updates on biosimilars.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.